Ascendis Pharma A/S
20-F February 11, 2026
Key Highlights
- Strong 55% revenue growth to $450 million in 2023, primarily driven by SKYTROFA®...
- Proprietary TransConâ„¢ technology platform provides a competitive advantage in ra...
- Significant pipeline catalysts include TransCon PTH PDUFA date (August 14, 2024)...
Read Analysis
🤖 AI Generated